Choose a language and wait for the translated text.
The agreement gives Zydus’ subsidiary, Sentynl Therapeutics option to acquire exclusive commercial rights of, ‘alvelestat’ for the treatment of AATD-LD (a rare genetic respiratory disease) in the US along with global manufacturing rights.
Zydus' subsidiary inks optional licensing agreement with Mereo BioPharma for rare respiratory drug | PharmaVoice
